Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC pursues firms advertising "free" product trials

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission follows through with its promise to enforce against marketers that falsely promise "free" product trials. The commission says it will announce Aug. 16 a lawsuit against a firm that allegedly marketed free trials of acai berry weight-loss and colon-cleansing supplements. FTC warned in February 2009 it would pursue firms that enrolled consumers in a "negative option" continuity program under which consumers are charged without consent for reoccurring shipments unless the consumer cancels. Marketers advertising acai products with negative option schemes caught the attention of Connecticut Attorney General Richard Blumenthal, the Center for Science in the Public Interest and the Council of Better Business Bureaus (1"The Tan Sheet" March 30, 2009)

You may also be interested in...



Acai Offered As Bait In Latest Marketing Scams To Draw Investigations

Trendy supplement ingredient acai is the latest lure in what the Federal Trade Commission calls "negative-option" online marketing scams

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel